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Diabetic nephropathy is a major risk factor for end-stage renal
disease and cardiovascular diseases and has a marked genetic
component. A common variant (D allele) of the angiotensin I-
converting enzyme (ACE) gene, determining higher enzyme levels,
has been associated with diabetic nephropathy. To address cau-
sality underlying this association, we induced diabetes in mice
having one, two, or three copies of the gene, normal blood
pressure, and an enzyme level range (65–162% of wild type)
comparable to that seen in humans. Twelve weeks later, the
three-copy diabetic mice had increased blood pressures and overt
proteinuria. Proteinuria was correlated to plasma ACE level in the
three-copy diabetic mice. Thus, a modest genetic increase in ACE
levels is sufficient to cause nephropathy in diabetic mice.
The vast extent of human genetic variability is becomingincreasingly obvious as the human genome project
progresses (1, 2). Accordingly, much effort is being placed on
uncovering genetic variations that influence the risk for or
progression of the common but complex disorders of human-
kind, such as atherosclerosis, hypertension, diabetes, and cancer.
Identification of genetic variants associated with these condi-
tions is expected to lead to improved diagnostic capabilities and
more selective treatments, and even to avoidance of the condi-
tions (3). A major difficulty already encountered in this type of
study in humans is the difficulty of establishing causation, as
distinct from association and genetic linkage. Useful practical
options can often be devised from associations without proof or
knowledge of causation, but definitive advances depend on
establishing causation. A valuable approach to establishing
causative links between human genetic variants and conditions
of interest is to introduce functionally similar genetic variations
into mice, combine these variations with any other necessary
predisposing factors, and determine whether the candidate
genetic variation directly causes the condition of interest. Once
proof of causality is established, further studies, often impossible
in humans, become practical in animal models and can lead to
an ascertainment of molecular mechanisms. Here we apply this
approach to a putative causal link between a common genetic
polymorphism in the gene coding for the angiotensin I-convert-
ing enzyme (ACE, kininase II) and diabetic nephropathy.
Diabetic nephropathy develops in 30–50% of type 1 and in
about 10% of type 2 patients who have had diabetes mellitus for
10–20 years (4). This disease is the most common cause of
end-stage renal disease in the United States and Europe, and the
presence of elevated microalbuminuria, an early marker of
diabetic nephropathy, or overt proteinuria further increases the
risk for cardiovascular disease in patients with diabetes by at least
3-fold (5, 6). The etiology of diabetic nephropathy is poorly
understood, but family studies have suggested a genetic predis-
position (7, 8), and numerous studies have sought associations
between its incidence and a variety of genetic polymorphisms. Of
these, the most robust has been an association between nephrop-
athy in type 1 diabetics and the D allele of an insertiondeletion
(ID) polymorphism in intron 16 of the ACE gene (9–12). This
polymorphism, first described in 1990 by Rigat et al. (13), is itself
associated with differences in the plasma and tissue levels of
ACE (II, 76%; ID, 100%; DD, 126% of average). These
associations suggest that a high constitutive level of ACE is
deleterious to the kidney in the setting of chronic hyperglycemia,
but a causal link between higher levels of ACE and kidney
malfunction in association with diabetes has not been estab-
lished. To address this issue, we therefore used streptozotocin to
induce diabetes in mice with modest genetically determined
differences in their plasma ACE levels already caused by their
having one, two, or three functional copies of the ACE gene at
its normal chromosomal location (14).
Materials and Methods
Generation of Mice with One-Three Copies of the ACE Gene. Genet-
ically engineered mice carrying either an inactivation or a
duplication of the ACE gene on chromosome 11 were used for
the study (14). Heterozygous mice of each strain were crossed for
eight generations with wild-type C57BL6 mice (IFFA CREDO,
Les Oncins, France) and among themselves to generate the
experimental groups. Genotyping of each animal was performed
by PCR and Southern blotting as described (14). Mice carrying
either one (one-copy), two (two-copy), or three (three-copy)
functional ACE gene copies were studied. We were unable to
obtain, for unknown reasons, sufficient numbers of viable mice
homozygous for the ACE gene duplication to include in the
study.
Induction of Diabetes and Follow-Up of Animals. Diabetes was
induced in groups of 10–12 3-month-old female mice of each
genotype by 4–7 daily i.p. injections of streptozotocin (Sigma
Aldrich, L’Isle d’Abeau, France), at a dose of 80 gg body
weight in 8 l of sterile 0.05 M sodium citrate (pH 4.5). Control
groups of eight animals of each genotype received an equal
volume of vehicle. Blood glucose levels (One Touch II glucom-
eter, LifeScan, Mountain View, CA) and urinary glucose and
ketonuric acid concentrations (Keto-Diabur-Test 5000, Roche
Molecular Biochemicals) were monitored daily during strepto-
zotocin or vehicle treatment and every 2 weeks thereafter.
Approximately 80% of the streptozotocin-treated mice in each
group developed stable hyperglycemia accompanied by mild
ketonuria. Two diabetic and one control mice died during
follow-up.
Mice were studied for 12 weeks without insulin treatment.
They were fed ad libitum standard mice chow containing 0.4%
of Na and 26% of mixed protein including 6% fish protein (Usine
d’Alimentation Rationnelle, Paris) and had free access to tap
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water. Before diabetes induction and at 2 weeks of diabetes, a 20
l blood sample was obtained by orbital puncture for the
determination of plasma ACE activity. Mice were placed in
metabolic cages (Marty Technology, Paris, France) every 2
weeks for the determination of albumin excretion in 24-hour
urine. At 12 weeks, 3 days after a last urine collection, animals
were killed (0.1 mgg ketamine and 0.01 mgg xylazine, i.p.), and
blood was collected by orbital puncture. The left kidney and the
two lungs were excised rapidly and frozen in liquid nitrogen for
mRNA analyses. The right kidney was fixed by immersion in
Bouins’ solution for histological studies.
The procedures for the care and euthanasia of animals were
in accordance with the European Community standards for the
care and use of laboratory animals.
Blood Pressure Measurement. Blood pressure was measured in
conscious-trained mice on 3 consecutive mornings each month
by the tail-cuff method, using a PowerLaboS system connected
to CHART software (A. D. Instruments, Milford, MA) as de-
scribed (15). Twenty consecutive measurements were averaged
on each day, and the mean value of the 3 days was calculated for
each mouse.
Biochemical and Hormonal Determinations. Plasma and urine cre-
atinine were measured by automated enzymatic methods
(Kodak Biolyzer, Eastman Kodak). Urinary albumin concentra-
tion was measured by laser immunonephelometry (12), using a
rabbit anti-mouse albumin Ab (ICN).
Plasma ACE activity was measured spectrophotometrically
with hippuril-histidine-leucine as substrate (16). Plasma renin
concentration (PRC) and urinary kallikrein excretion were
determined by radioimmunoassays of the peptides generated in
the presence of an excess of the corresponding substrates
(15, 17).
Quantification of ACE mRNA in the Lung and Kidney. Lung and kidney
RNA extraction and Northern blot analyses of ACE mRNA,
using a rat ACE cDNA probe, were carried out as described (16).
The ACE mRNA signal was normalized to that of glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) mRNA by using a
human GAPDH cDNA probe (CLONTECH). Quantification of
the hybridization signals was performed by solid-phase counting
(InstantImager, Packard).
Histological and Morphometric Analyses of the Kidney. Kidneys were
cut transversally, fixed in alcoholic Bouins’ solution, and em-
bedded in paraffin. Sections, 5 m thick of the entire kidney,
were stained with Masson’s trichrome for quantitative histology
and with periodic acid-Schiff for morphometric analysis by using
computerized image analysis (18). The following parameters
were measured: total glomerular surface area delimited by the
internal edge of the Bowman’s capsule; glomerular tuft surface
area defined by the total glomerular surface area minus the
urinary space area and the urinary recesses; mesangial surface
area defined by the glomerular tuft surface area minus the areas
of the capillary lumens and the glomerular capillary free walls;
and Bowman’s capsule surface area and mean thickness of the
Bowman’s capsule.
Statistical Analysis. Results are presented as mean  SEM. For
parameters measured at different times after onset of diabetes,
blood pressure, and albuminuria, statistical comparison was
performed by using a multiway ANOVA test with diabetes, ACE
genotype, and time as test factors (STATVIEW 4.5 software;
Abacus Concepts, Berkeley, CA). For other parameters mea-
sured at the time of death at 12 weeks, a 2-way ANOVA test was
performed with diabetes and ACE genotype as factors. The
ANOVA tests were followed when appropriate by Fisher’s tests
for comparisons among multiple groups. Correlation between
variables was tested by linear regression analysis. Statistical
significance was achieved if P  0.05.
Results and Discussion
Effect of Diabetes on Plasma ACE and ACE mRNA. Diabetic levels of
plasma glucose were present throughout the 12-week observa-
tional period in streptozotocin-treated mice of all 3 ACE geno-
Table 1. Main biochemical parameters in plasma and urine and renal morphometric data 12 weeks after induction of diabetes
One-copy Two-copy Three-copy P values*
CT (n  8) DM (n  11) CT (n  8) DM (n  6) CT (n  7) DM (n  7) Genotype Diabetes Interaction
Body weight, g 22.5  0.5 18.3  1.1 21.8  0.5 21.0  0.6 22.7  0.7 20.3  0.3 0.27 0.001 0.08
Plasma
Glucose, mmoll 7.2  0.3 27.5  1.2 7.4  0.3 23.5  1.0 6.9  0.3 24.4  1.6 0.18 0.0001 0.07
Hematocrit, % 43.1  0.8 44.9  1.8 43.2  0.8 44.5  1.7 43  0.6 42.9  2.3 0.82 0.25 0.65
Creatinine, moll 13.1  1.1 16.3  1.3 11.5  1.1 15.5  0.8 14.7  1.4 16.7  0.8 0.21 0.01 0.71
PRC, gAImlh 1.29  0.14 0.94  0.17 0.82  0.13 0.78  0.18 0.86  0.12 0.59  0.11 0.03 0.07 0.57
Urine
Urine volume, ml24 h 0.5  0.1 19.3  3.5 0.5  0.1 13.0  1.5 0.7  0.1 19.4  2.7 0.14 0.0001 0.18
Creatinine clearance, lmin 127  32 224  33 142  26 187  16 139  22 237  21 0.72 0.001 0.59
UKE, gBKmin24 h urine 1.49  0.39 1.48  0.23 1.59  0.31 2.10  0.39 2.94  0.76 3.31  0.32 0.01 0.06 0.13
Kidney weight
Absolute, mg 120  4 164  7 112  3 140  7 124  13 176  3 0.01 0.0001 0.25
Relative, mgg BW 5.4  0.1 9.2  0.5 5.1  0.1 6.7  0.3 5.4  0.6 8.7  0.1 0.01 0.0001 0.16
Morphometric data
Glomerular tuft surface area, m2 2226  58 2785  103 2284  67 2553  80 2077  71 2555  93 0.11 0.0001 0.08
Mesangial surface area, m2 531  33 571  32 598  19 571  26 585  27 630  31 0.20 0.63 0.23
Bowman’s capsule surface
area, m2
207  8 304  41 292  9 336  14 291  14 377  20 0.01 0.0001 0.56
Mean thickness of Bowman’s
capsule, m
2.56  0.12 2.01  0.22 2.07  0.07 1.70  0.04 2.03  0.10 1.69  0.09 0.03 0.0001 0.9
CT, control groups; DM, diabetic groups; Creat, creatinine; PRC, plasma renin concentration; UKE, urinary kallikrein excretion. Results are means  SEM; AI,
angiotensin I; BK, bradykinin; BW, body weight.
*Two-way ANOVA.











types but not in the untreated controls (Table1; P of treatment 
0.0001). The induction of diabetes by streptozotocin was not
affected by ACE gene copy number (P of genotypic effect 
0.18).
Fig. 1A summarizes the differences in plasma ACE activity
in the one-, two-, and three-copy diabetic mice and the
untreated controls. In agreement with published data (14), the
plasma ACE activity of the untreated animals is directly
related to their ACE gene copy number ranging from an
average of 65% in the one-copy mice to 162% in the three-copy
mice relative to the wild-type two-copy mice (P of genotypic
effect  0.0001). In humans, diabetes has been associated with
elevated ACE activity (19), and we find this in our mice. Thus,
induction of diabetes causes increases in plasma ACE activity
of 70  10, 174  18, and 267  32 milliunitsml in the one-,
two-, and three-copy mice, respectively (P of diabetes effect 
0.0001). Additionally, the present study shows that the extent
of the increase is affected by the ACE genotype (P of
interaction between diabetes and genotype  0.001) with the
effect being greatest in the three-copy and least in the one-
copy animals.
Possible explanations of this ACE genotype-dependent in-
crease in the plasma ACE activity in the diabetic mice are that
diabetes causes an increase in ACE production andor a
decrease in the clearance of ACE from the blood, which is
inf luenced by the ACE genotype. To help distinguish between
these possibilities, we determined ACE mRNA levels in the
lung (the primary source of plasma ACE) and in the kidney,
a quantitatively minor source. Fig. 1B shows that ACE mRNA
in the lung parallels the plasma ACE activities and highly
depends on the ACE gene copy number (P of genotype 
0.0001), but the lung ACE mRNA is not affected by the
induction of diabetes (P  0.6). The kidney ACE mRNA (Fig.
1C) also depends on gene copy number (P of genotype  0.01),
but in this tissue its amount is decreased slightly (25%) by the
diabetes (P of treatment  0.01), most probably by a decrease
in ACE gene expression in the proximal tubule, the major site
of ACE synthesis in the kidney (20). We conclude from these
observations that the increase in plasma ACE activity accom-
panying the induction of diabetes is unlikely to be caused by an
increased level of ACE production. The simplest hypothesis is
that the clearance of ACE (21) is decreased by the effects of
diabetes, and that these effects are rapid (already maximal at
2 weeks; Fig. 1 A) and are greater when ACE plasma activities
are higher. Thus, in diabetes, a genotype-dependent increase
in circulating ACE can inf luence renal function.
Effect of ACE Gene Copy Number on Blood Pressure. Fig. 2A com-
pares the changes with time of the blood pressures, measured by
tail cuff, of one-, two-, and three-copy mice after streptozotocin
treatment with the pressures of the untreated controls. The
blood pressures of the untreated mice are not affected by ACE
gene copy number (P of genotype effect in control groups 
0.63), which is in agreement with previous observations (14). Nor
are the blood pressures of the wild-type (two-copy) mice and the
one-copy mice with genetically lower ACE activity significantly
affected by induction of diabetes. However, the blood pressures
of the three-copy diabetic mice with genetically higher ACE
activity increase with time, and 12 weeks after the induction of
diabetes are 10–20 mmHg higher than the blood pressures of the
one and two copy diabetic mice or the control mice of all three
genotypes (P of genotype effect in diabetic groups  0.001). We
conclude that, although the higher level of ACE gene function in
the three-copy mice does not normally affect their blood pres-
sure, it causes blood pressure to increase in the presence of
diabetes.
Effect of ACE Gene Copy Number on Urinary Albumin Excretion (UAE)
and Other Renal Parameters. The earliest indicator of renal in-
volvement in diabetes is an increase in the level of UAE (4). Fig.
2B compares the UAE of one-, two-, and three-copy mice after
streptozotocin treatment with that of their untreated controls.
The one-, two-, and three-copy control mice have very low levels
of UAE (10 g24 h), which do not change significantly with
time. Two weeks after induction of diabetes, the one- and
two-copy mice have UAE levels (66  5 and 70  7 g24 h)
7 higher than the control mice (P vs. untreated  0.0001),
which increases slowly to 113  19 and 107  16 g24 h 10
Fig. 1. Plasma ACE level and ACE mRNA in control ()
and diabetic (■ ) mice having one (1-C), two (2-C), or
three (3-C) copies of the ACE gene. (A) Plasma ACE
activity was measured before diabetes induction and
at 2 and 12 weeks. Results are means  SEM. Effect of
genotype or diabetes, P  0.001; interaction between
genotype and diabetes, P  0.001. (B and C) ACE mRNA
levels were measured in the lung and kidney at 12
weeks. Results are normalized to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) mRNA level. (B)
Lung. Effect of genotype, P  0.0001; effect of diabe-
tes, P  0.6. (C) Kidney. Effect of genotype or diabetes,
P  0.01.
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weeks later. In marked contrast, the UAE of the three-copy
diabetic mice, already nearly twice that of the one- and two-copy
diabetic mice, increases rapidly over the next 10 weeks, reaching
a level of 380  48 g24 h. At the 12-week time point, UAE was
significantly correlated with plasma ACE levels in the three-copy
diabetic mice (r  0.89, P  0.01). Thus, the modestly higher
ACE level of the three-copy mice causes the three-copy mice
when diabetic to develop overt albuminuria early in the course
of the disease. In contrast, the UAE of the one- and two-copy
diabetic mice progresses much less rapidly.
We compared various biochemical parameters in plasma and
urine and kidney morphometry in the normal and diabetic
one-, two-, and three-copy mice with two aims: first, to
determine how similar the induced changes are to those seen
in human diabetics, and second, to uncover the effects of ACE
genotype, of diabetes, and of any interactions between the
effects of diabetes and the ACE genotype. The results of these
comparisons are presented in Table 1. Body weight, plasma
glucose, urine volume, and creatinine clearance are all signif-
icantly affected (P  0.01–0.001) in the expected directions by
the induction of diabetes, but not by the ACE genotype.
Absolute and relative kidney weights are increased by diabetes
(P  0.0001), but we found no evidence in the kidney weights
of any interaction between diabetes and the ACE genotype
(P  0.25). Plasma renin concentration was increased in the
ACE one-copy animals (P of genotype 0.03), as reported (14),
and tended to decrease with diabetes (P  0.07) but with no
evidence of interaction (P  0.57). Urinary kallikrein signif-
icantly increased with increase in ACE copy number (P  0.01)
and tended to increase with diabetes (P  0.06), but again with
no evidence of interaction (P  0.13). Light microscopy
observations revealed glomerular hypertrophy without overt
glomerulosclerosis in the diabetic mice, and only slight and
sporadic interstitial fibrosis and tubular atrophy. Diabetes
significantly increased (P  0.0001) the total glomerular
surface area, the glomerular tuft surface area, and the surface
area of Bowman’s capsule. These lesions are similar to those
observed at the earliest stage of diabetes in humans (22).
Mesangial morphology was not altered. There was a significant
positive relationship between Bowman’s capsule surface area
and ACE genotype in both control and diabetic mice (P 
0.01). However, no interaction between the genotype and
diabetes was observed for any of the morphological parame-
ters. We conclude that the changes in kidney morphology
observed in our diabetic mice are similar to those seen in the
initial stages of human diabetes, but that these kidney struc-
tural changes are not affected by the ACE genotype. Thus, the
proteinuria observed in the three-copy diabetic mice must
arise from an increased glomerular permeability without
structural injury that can be detected by light microscopy.
Mechanism of ACE-Mediated Renal Dysfunction in Diabetes. Some
potentially useful inferences can be drawn from our present
studies when combined with previous observations on the
marked differences in the effects of changes in ACE activity on
the steady-state levels of the substrates of ACE (angiotensin I
and bradykinin; ref. 23) and its products (angiotensin II and
bradykinin 1–7). Experimental data from rats (24) and com-
puter simulations and experimental data from mice (25) have
indicated that modest changes in ACE activity in either
direction affect the level of the substrates of the enzyme
(including bradykinin), but have little effect on the level of its
products (including angiotensin II), which are only signifi-
cantly affected when ACE function is more substantially
decreased. These considerations together with our present
data lead us to suggest that bradykinin levels, which decrease
when ACE levels are genetically increased, may be more
immediately important than angiotensin II levels in the causal
chain between genetically higher ACE levels and the devel-
opment of diabetic proteinuria in mice. This suggestion is
supported by the close anatomic juxtaposition of the kal-
likrein-producing cells in the late distal tubule with renal
glomerular arterioles (26), and by experiments showing that
the kinin system markedly affects glomerular hemodynamics
in diabetic animals (27). Direct tests of the idea should be
possible in mice by determining the effects on diabetic ne-
phropathy of experimentally manipulating the kinin system.
Nevertheless, it is also important to consider the possibility
that increased intrarenal formation of angiotensin II, a potent
regulator of glomerular hemodynamics (28), mediates the
deleterious effect of the ACE gene, given the unique features
of the renal circulation with regard to both high renin and
angiotensin I concentration and low ACE content, and exper-
imental evidence showing that the renal distribution of ACE
protein is markedly affected by diabetes (20, 29).
Fig. 2. Evolution of blood pressure and UAE during diabetes in mice
having one, two, or three copies of the ACE gene. (A) Blood pressure was
measured in conscious-trained mice. Results are means  SEM. Groups are
one- ({), two- (), or three- (E) copy control nondiabetic mice; and one-(}),
two-(■ ), or three-(F) copy diabetic mice. Effect of diabetes, P  0.05;
interaction between genotype and diabetes, P  0.01 (multiway ANOVA).
Effect of genotype in control groups, P  0.63; and in diabetic groups, P 
0.001 (two-way ANOVA). *, P  0.05, three-copy diabetic group compared
with other diabetic groups. (B) UAE was measured on 24-h urine. Presen-
tation of data is the same as in A. Effect of diabetes, genotype, or time, P 
0.0001. Interaction between genotype and diabetes, P  0.0001. Effect of
genotype in control groups, P  0.30; and in diabetic groups, P  0.001. *,
P  0.05; **, P  0.01; ***, P  0.0001, three-copy diabetic group compared
with other diabetic groups.











We conclude that the observations reported here establish a
causal link between a genetically determined modest increase in
ACE gene function and the development of proteinuria in
diabetic mice. This causal link has considerable relevance to the
effects of the insertiondeletion ACE polymorphism in human
diabetics, in that it establishes that higher ACE levels are
sufficient to initiate the chain of events leading to diabetic
nephropathy. The three-copy mice should provide a valuable
model for helping determine the molecular, microvascular, and
other physiological steps involved in this process and in deter-
mining how best to intervene.
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